Amgen's Phase 3 trial of bemarituzumab plus chemo met its survival goal in FGFR2b+ gastric cancer, with full data expected ...

They also have strong dividend track records. Apple and Amgen have lagged the market over the trailing-12-month period, but despite their issues, both stocks are worth investing in for the long haul.